加载中
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
常规交易时段
US$9.27
+US$0.15 · +1.64%
盘中时间采用ET。市场数据可能有所延迟。
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
日内区间
当前US$9.27
52周区间
当前US$9.27
盘中时间采用ET。市场数据可能有所延迟。
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
日内区间
当前US$9.27
52周区间
当前US$9.27
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | — | 1.67万 USD |
| 销货成本 | — | — | 1044.5万 USD | — | 585.15万 USD |
| 毛利 | — | — | −1044.5万 USD | — | −584.33万 USD |
| 研究与开发 | 3337.93万 USD | 1063.8万 USD | 788.32万 USD | 160.87亿 USD | 494.92万 USD |
| 销售、一般及管理费用 | 678.8万 USD | 618.95万 USD | 637.96万 USD | 72.93亿 USD | 331.34万 USD |
| 营业费用 | 4016.73万 USD | 1682.75万 USD | 845.27万 USD | 233.8亿 USD | 463.29万 USD |
| 利息收入 | — | — | — | — | 4731 USD |
| 利息支出 | — | 7.68万 USD | 20.14万 USD | 2.82亿 USD | 41.63万 USD |
| 折旧和摊销 | — | — | 2.12万 USD | 1.44万 USD | 5.67万 USD |
| 营业利润 | −4016.73万 USD | −1682.75万 USD | −1889.77万 USD | −233.8亿 USD | −1056.69万 USD |
| 净利润 | −3971.91万 USD | 277.89万 USD | −1750.61万 USD | −180.62亿 USD | −1197.95万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$31.00
上涨空间 234.41%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年11月28日 | 1:25 | — | — |
股票拆分 | 2022年6月28日 | 1:60 | — | — |
已生效 2025年11月28日
1:25
已生效 2022年6月28日
1:60
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
